Abstract
Introduction
The heparin-binding growth factors-basic and acidic Ž . fibroblast growth factor bFGF and aFGF, respectivelyare potent angiogenic agents and promote growth of vascuw x lar smooth muscle cells and endothelial cells 1 . Intracoronary treatment with bFGF increased microvessel numbers w x in infarcted and non-infarcted myocardium in pigs 2 . Basic FGF reduced the size of acute myocardial infarction and increased the density of arterioles and capillaries in the w x infarcted area 3 . Chronic application of acidic FGF did ) Ž . Ž . Corresponding author. Tel.: q49 6221 568611; fax: q49 6221 565515; e-mail: ctiefenbacher@krzmail.krz.uni-heidelberg.de not cause angiogenic responses in viable myocardium but induced smooth muscle cell hyperplasia in ischemic areas w x 4 . Intracoronary injection of bFGF enhanced collateral blood flow via its angiogenic effects in the canine myw x ocardium 5 . Basic FGF also appears to protect vascular function in the setting of ischemia, because chronic administration increased endothelium-dependent relaxation of the w x collateral perfused coronary microcirculation 6 . Apart from angiogenic and mitogenic effects, there are recent reports about direct vascular effects of FGF. Basic FGF w x dilated rat pial arterioles 7 and systemic administration of ( )w x both aFGF and bFGF caused hypotension in rats 8 . Administration of bFGF to isolated coronary arterioles Ž . only produced modest 7% dilation at doses above the w x physiological range 6 . Basic FGF has also been demonw x strated to induce rat aortic contraction 9 . Little is known about direct vascular effects of aFGF.
The stimuli for the formation and release of FGFs are not known. FGFs are primarily stored in the endothelial w x basement membrane, extracellular matrix 10 and mast w x cells 11 and bind to heparin with an unusually high w x affinity 12 . Heparin refers to a group of negatively charged proteoglycans mainly produced by mast cells. These macromolecules are known to have a variety of biological effects such as inhibition of smooth muscle cell w x proliferation 13 , prevention of thrombosis and induction w x of hypotension 14 . The role of heparin and heparin-related proteoglycans such as heparan sulfates for the availability and signal transduction of FGF seems to be complex. Heparin protects FGFs from proteolytic degradation w x 15 , increases the release of FGF from the extracellular w x w x matrix 16 and mast cells 11 , and binds to the FGF w x receptor itself 17 . Furthermore, binding of FGF to cellsurface heparin-like molecules seems to be crucial for an adequate binding of FGF to its high-affinity receptors to w x induce a biological response 18,19 . Additionally, heparin-like molecules bind FGFs in the extracellular maw x w x trix to store them 20 and act as transporters of FGFs 21 . Interestingly, the concentration of heparin in the endothew x lial cell is 100 times that in plasma 22 and heparin itself has angiogenic and vasoactive properties. Heparin treatment enhanced NO production in human endothelial cells w x 23 , enhanced coronary collateral development in pigs w x after coronary artery occlusion 24 , and lowered blood w x w x pressure in hypertensive patients 14 and rats 25 .
Taken together, there is evidence in the literature indicating that FGF's and heparin possess important roles in angiogenesis. There also is the suggestion that these factors are vasoactive, but there has not been conclusive evidence for this action in the coronary circulation. We, Ž . therefore, proposed the following hypotheses: 1 fibroblast growth factors produce vasoactive responses in coro-Ž . nary arterioles; 2 heparin exerts a similar action to FGF, because this negatively charged glycosaminoglycan facilitates both the release of FGF from the cardiac extracellular Ž . matrix and its binding to a high-affinity receptor; 3 acidic and basic FGF and heparin signal through the production of nitric oxide. reservoir connected to each micropipette. This pressure approximates the estimated intraluminal pressures for miw x crovessels of this size in vivo 27 . By setting both reservoirs to the same height, the vessels were pressurized without flow. Leaks were detected by closing off the system to the reservoirs and examining for a decline in intraluminal pressure. Vessels with leaks were excluded from further study. Internal diameters were recorded continuously during experiments. The microvessels were set to their in situ length and were bathed in PSS-albumin solution with the temperature maintained at 36-378C by an external circulating heat bath. Arterioles prepared in this manner developed spontaneous tone of 25-30% of maximal diameter. After equilibration of the vessels, vasodilatory responses to the endothelium-dependent vasodilator, Ž y5 . serotonin 5HT; 10 M , and to the endothelium-indepen-Ž y5 . dent vasodilator, sodium nitroprusside 10 M , were obtained to assess normal endothelial and smooth muscle function of the vessels. We elected to use 5HT because we have previously found that the dilation to 5HT is mediated by the production of NO, inasmuch as the response can be w x blocked by inhibitors of NO production 26 .
Methods

General preparation
This 
Drugs
The following drugs were used in this study: acidic and basic FGF from Life Technologies dissolved in sterile Ž . water and diluted in PSS without albumin . Heparin from ElkinsrSinn; 5HT, nitroprusside, L-NMMA, glibenclamide Ž and indomethacin from Sigma diluted in PSS without . albumin . Antibodies against FGF and its receptor were obtained from Upstate Biotechnology, purified via immunoprecipitation and used after dilution in PBS. Additionally, responses to the doses of bFGF, aFGF and heparin were obtained under baseline conditions and after Ž pretreatment with a monoclonal anti-FGF antibody 10 . mgrml and after pretreatment with an FGF-receptor anti-Ž . body 10 mgrml .
Experimental protocols
In all experiments, vascular responses to 5HT and Ž y5 . nitroprusside both 10 M were obtained under baseline conditions and after pretreatment with the different inhibitors. Although we did not establish the effectiveness of the specific blockade to indomethacin and glibenclamide with challenges by arachidonic acid or cromokalim, respectively, it was previously established that the doses of these antagonists that we employed produce efficacious blockade of the desired enzyme or channel in isolated w x coronary arterioles 26,28 . Moreover, we believed the blockades to be specific because the responses to serotonin and nitroprusside were not affected by these two antagonists.
Data analysis
Responses to the various agonists were assessed as percent dilation over baseline using the calculation:
Diameter after agonist y baseline diameter Ž .
r maximal diametery baseline diameter = 100.
Ž .
Baseline diameter was defined as that prior to adminis-Ž tration of the vasodilatory agonist e.g., that occurring with . spontaneous tone or that during L-NMMA . The percent dilation values were compared by two-way repeated measures ANOVA. All statistics were computed using Statview 4.1 on a Macintosh 8100 computer. A probability level of 5% was used in all studies as the criterion of statistical significance.
Results
Vessel diameter
Arterioles investigated in this study had a maximal diameter of 89 " 5.1 mm and after developing spontaneous tone 65.5 " 3.8 mm. Neither pretreatment with indo-Ž y5 . Ž y 5 . methacin 10 M , glibenclamide 10 M , the mono-Ž . clonal anti-FGF antibody 10 mgrml or the FGF receptor Ž . antibody 10 mgrml did significantly affect basal vascu-Ž y4 . lar tone. L-NMMA 10 M caused in all vessel preparations a significant vasoconstriction of about 15%. Vascular relaxation to both 5HT and nitroprusside was between 90 and 100% in control experiments as well as after pretreatment with indomethacin, glibenclamide, the FGF receptor antibody or the monoclonal anti-FGF antibody. The response to 5HT, but not that to nitroprusside, was signifi-Ž . cantly reduced after pretreatment with L-NMMA 7 " 6% , indicating significant inhibition of NO synthesis. 
. Ž laxation; P s 0.997 or glibenclamide n s 9; 54 " 7%;
. P s 0.799 . Pretreatment with L-NMMA caused a signifi-Ž . cant reduction in baseline diameter n s 11; y16 " 6% . The effect of bFGF was completely inhibited after L-NMMA pretreatment.
In contrast, aFGF did not have any significant effect but Ž rather tended to cause a minor vasoconstriction n s 13;
. y5 " 3%; n.s. under baseline conditions. Following administration of the inhibitors, aFGF still did not elicit any significant vasoactive responses. Ž sponse to heparin was significantly reduced 78 " 5%;
. P s 0.0132 .
The effects of 5HT and nitroprusside were unaltered after pretreatment with monoclonal anti-FGF antibodies.
( ) 3.5. Effects of FGF-receptor antibodies Fig. 4
After incubation with specific FGF-receptor antibodies Ž . for 15 min n s 10 , the response to bFGF was completely Ž inhibited maximum 5 " 3%; P -0.001 versus control . response . Again, there was no significant effect of aFGF Ž . 0 " 3%; n.s. . Interestingly, application of the FGF-recep- w x 29 and arteriolar 6,7 dilation. Our study significantly extends these findings into coronary resistance vessels by showing the potent vasodilatory effect of bFGF on coronary arteriolar tone. The signalling pathways have not been systematically investigated; possible transduction mechanisms have been suggested to include production of NO w x w x 1,8 , increase in intracellular calcium 29 and activation w x of ATP-sensitive potassium channels 8 . Basic FGF caused dose-dependent relaxation in our study which was inhibited by pretreatment with L-NMMA, but not by pretreatment with indomethacin or glibenclamide. Importantly, none of these substances altered smooth muscle function, inasmuch as dilation to sodium nitroprusside was not affected by these antagonists. Furthermore, the effect of bFGF could be significantly inhibited by application of monoclonal anti-FGF antibodies as well as specific FGF receptor antibodies, indicating a specific effect of bFGF mediated via specific FGF receptors. These results are in w x agreement with findings of Rosenblatt et al. 7 who showed a direct vasodilating effect of bFGF in rat pial w x arterioles and Cuevas 8 who found a hypotensive effect of bFGF in rats which could be inhibited by either L-NAME w x or glibenclamide. Furthermore, in a study by Ku et al. 29 , the effects of VEGF could also be inhibited by L-NAME w x and not by indomethacin. Sellke et al. 6 showed an enhancement of flow in collateral perfused coronary microvessels by chronic bFGF treatment in a pig model of chronic coronary artery occlusion. In contrast to our observations that bFGF is a potent vasodilator, a maximal dose Ž . of bFGF caused only a small relaxation about 7% which was completely inhibited by pretreatment with L-NAME Ž y4 . 10 M . Although it is not easy to resolve differences between the two studies, we are compelled to point out that Sellke et al. preconstricted arterioles with the thromboxane agonist, U 446419, which in our experience makes vessels less susceptible to vasodilators. Also, the fact that these arterioles were isolated from control areas of hearts with chronic occlusion of a coronary artery may contribute to the differences in results-i.e., is the non-ischemic area truly representative of a control area? And finally, we used a subthreshold dose of heparin to act as chaperone for FGF through, and prevent its binding to, the extracellular matrix. This maneuver is important because without heparin we had found extreme variation in vasodilation to the mitogens. Taken together, there are many reasons to account for the differences between the vasodilatory potency of bFGF in our study versus that of Sellke et al.
Heparin and heparin-related proteoglycans are widely distributed in the body and are associated with extracellular matrix, basement membranes, mast cells, endothelial w x cells and almost all cell surfaces 14 . They interact with many biological proteins and have a plethora of vascular effects. The proteoglycan lowers blood pressure in rats w x w x 14,31 and in hypertensive patients 32 , interacts with the w x renin-angiotensin system 32,33 , modulates arachidonic w x acid metabolism 25 , increases collateral flow via promotw x ing angiogenesis 24 and induces NO synthesis in enw x dothelial cells 14 . We cannot help but mention that none of these studies elucidated a vascular action of heparin on resistance vessels, and any hypotensive effect could be Ž modulated by a plethora of hemodynamic actions e.g., . vasodilation affecting levels of pressor hormones, negative inotropic influences, venodilation, etc. Our results impact on these observations by showing that one of the hypotensive effects of heparin may be attributed to a direct vasodilatory effect on resistance vessels.
In this study, we demonstrated for the first time a direct vascular effect of heparin causing dose-dependent vasodilation in isolated coronary arterioles. This effect is partially mediated by NO synthesis as well as by activation of ATP-sensitive potassium channels as demonstrated by significant inhibition of the heparin-induced vasodilation by pretreatment with both L-NMMA and glibenclamide. These w x data are supported by results of Yokokawa et al. 23 , showing an enhanced cGMP production via an NO-mediated pathway by heparin in cultured endothelial cells as w x well as by findings of Ito et al. 34 demonstrating an interaction between heparin and potassium channels in isolated myocytes. We are compelled to point out that our conclusion regarding the involvement of NO in heparin-induced dilation is not totally decisive. The large decrease in baseline diameter produced by L-NMMA could have potentially skewed the results. In the presence of the antagonist, the percent relaxation produced by heparin was significantly attenuated. However, the absolute magnitude of dilation was less affected. One could argue that the effects of L-NMMA are exclusively due to the changes in baseline diameter. We do not support this contention, because a component of heparin-induced dilation was blocked by the antibodies to FGF or its receptor, of which the dilation was mediated exclusively by NO. We still maintain that heparin induces NO relaxation via this mechanism.
Heparin and its derivatives either free in solution or bound to the cell surface are known to be essential for the effects of FGF. FGFs have been shown to possess FGF-rew x ceptor binding-and heparin-binding domains 35,36 . In our experiments, the vasodilatory effect of heparin was significantly reduced by an antibody to FGF and, even more pronounced, significantly blocked by pretreatment with specific FGF receptor antibodies. These data most likely indicate that part of the heparin-induced vasodilation is mediated via bFGF. This is supported by results demon-Ž . strating that: 1 heparin is involved in the release of bFGF w x Ž . from mast cells and extracellular matrix 11 ; 2 heparin w x Ž . acts as a transporter of FGF to the cells 21 ; 3 interaction of FGF with cell-membrane-bound heparin derivatives is an essential requirement for the binding of FGF to the w x Ž . high-affinity receptor 18,19 ; 4 heparin itself binds to the w x Ž . high-affinity FGF receptor 17 ; and 5 FGF can be internalized directly via cell-surface heparin derivatives w x independent of the FGF receptor 36 . From these observations in the literature and our own findings, we speculate that anti-FGF antibodies decrease the amount of bFGF which can be released by heparin andror transported to the cell binding sites. This impairs vasodilation. The heparin effect is not completely inhibited because the response to heparin is most likely only partially mediated by FGF and pretreatment with anti-FGF antibodies does also not completely inhibit the response to FGF itself. Pretreatment with the FGF-receptor antibodies allows FGF to bind to the low-affinity heparin-like receptors, but prevents binding to the specific FGF-tyrosine kinase receptors on the endothelial cell. In this case, the heparin response is mainly mediated by FGF-independent pathways, because the response to FGF itself was nearly completely inhibited after pretreatment with the receptor antibodies. Additionally, via blockade of the high-affinity FGF receptor, a possible binding of heparin to these receptors is prevented as well.
Taken together, our data demonstrate that basic FGF causes vasodilation of coronary arterioles by increasing endothelial NO production via specific FGF receptors. Heparin-dependent vasodilation is, in part, mediated by NO and also by activation of ATP-sensitive potassium channels. The effect of heparin is partially mediated via FGF receptors. In contrast to basic FGF, acidic FGF does not have vasodilating properties in isolated perfused coronary arterioles, but induces vasoconstriction when NO and prostaglandin synthesis is inhibited. We conclude from these data that basic fibroblast growth factor and heparin may be involved in the regulation of coronary microvascular tone acting partially through the same signalling mechanisms. The physiological and pathophysiological roles of these substances in the control of coronary resistance, however, remain to be elucidated. 
